SiBone (NASDAQ:SIBN) Insider Anshul Maheshwari Sells 11,228 Shares

SiBone (NASDAQ:SIBN) insider Anshul Maheshwari sold 11,228 shares of SiBone stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $20.02, for a total value of $224,784.56. Following the sale, the insider owned 234,920 shares of the company’s stock, valued at approximately $4,703,098.40. This represents a 4.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Anshul Maheshwari also recently made the following trade(s):

• On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The shares were sold at an average price of $19.55, for a total transaction of $112,353.85.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The stock was sold at an average price of $18.65, for a total transaction of $87,002.25.
• On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The stock was sold at an average price of $16.77, for a total transaction of $55,626.09.

SiBone Stock Performance

SiBone stock opened at $19.96 on Friday. The stock has a fifty day moving average price of $17.49 and a 200 day moving average price of $15.33. SiBone has a 52 week low of $11.48 and a 52 week high of $21.89. The firm has a market capitalization of $885.23 million, a P/E ratio of -58.71 and a beta of 0.66. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. The company had revenue of $56.01 million during the quarter, compared to the consensus estimate of $55.34 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. Equities research analysts anticipate that SiBone will post -0.4 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Truist Financial reaffirmed a “buy” rating and set a $23.00 price target (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. UBS Group boosted their price objective on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Finally, TD Cowen increased their target price on SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, SiBone has a consensus rating of “Moderate Buy” and a consensus target price of $24.17.

Institutional Investors Weigh In On SiBone

Several large investors have recently made changes to their positions in the business. Versant Capital Management Inc lifted its holdings in shares of SiBone by 102.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after acquiring an additional 887 shares in the last quarter. Bank of America Corp DE increased its holdings in SiBone by 8.7% in the 1st quarter. Bank of America Corp DE now owns 419,473 shares of the company’s stock valued at $5,298,000 after purchasing an additional 33,688 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in SiBone in the first quarter valued at about $159,000. Quantinno Capital Management LP raised its position in SiBone by 58.2% in the first quarter. Quantinno Capital Management LP now owns 29,475 shares of the company’s stock valued at $372,000 after purchasing an additional 10,848 shares during the period. Finally, First Light Asset Management LLC lifted its stake in shares of SiBone by 6.4% during the first quarter. First Light Asset Management LLC now owns 5,353,190 shares of the company’s stock worth $67,611,000 after purchasing an additional 320,286 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.